TELA Financials: TELA Bio Inc AI Analysis

Q: What are TELA Bio Inc's key financial statements?

According to the latest financial statement (Form-10K), TELA Bio Inc has a total asset of $86, Net loss of $-37

Q: What are the key financial ratios for TELA?

TELA Bio Inc's Current ratio is 1.48, has a Net margin is -53.62, sales per share of $2.41.

Q: How is TELA Bio Inc's revenue broken down by segment or geography?

TELA Bio Inc largest revenue segment is Soft-tissue Reconstruction Solutions, at a revenue of 58,453,000 in the most earnings release.For geography, United States is the primary market for TELA Bio Inc, at a revenue of 58,453,000.

Q: Is TELA Bio Inc profitable?

no, according to the latest financial statements, TELA Bio Inc has a net loss of $-37

Q: Does TELA Bio Inc have any liabilities?

yes, TELA Bio Inc has liability of 58

Q: How many outstanding shares for TELA Bio Inc?

TELA Bio Inc has a total outstanding shares of 39.39

Home

Stock

TELA

TELA Financial

TELA Bio Inc

$0.82

0.1%

$0

At close: Feb 11, 16:00:00 GMT-5

$0.81

-1.55%

$-0.01

Post-market: Feb 11, 19:09:13 GMT-5

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

TELA Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	77	69	58	41	29	18
Revenue Growth (YoY)	13%	19%	41%	41%	61%	20%
Cost of Revenue	25	22	18	14	10	6
Gross Profit	51	46	40	27	18	11
Selling, General & Admin	78	79	74	57	41	32
Research & Development	9	8	9	8	6	4
Operating Expenses	87	88	84	66	48	36
Other Non Operating Income (Expenses)	1	1	2	0	0	0
Pretax Income	-39	-37	-46	-44	-33	-28
Income Tax Expense	0	0	--	--	--	--
Net Income	-38	-37	-46	-44	-33	-28
Net Income Growth	-7%	-20%	5%	33%	18%	-7%
Shares Outstanding (Diluted)	45.42	28.52	22.86	16.27	14.47	12.93
Shares Change (YoY)	82%	25%	41%	12%	12%	13%
EPS (Diluted)	-0.85	-1.32	-2.04	-2.72	-2.3	-2.23
EPS Growth	-49%	-35%	-25%	18%	3%	-16%
Free Cash Flow	-31	-42	-41	-42	-31	-24
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	66.23%	66.66%	68.96%	65.85%	62.06%	61.11%
Operating Margin	-45.45%	-59.42%	-75.86%	-95.12%	-100%	-138.88%
Profit Margin	-49.35%	-53.62%	-79.31%	-107.31%	-113.79%	-155.55%
Free Cash Flow Margin	-40.25%	-60.86%	-70.68%	-102.43%	-106.89%	-133.33%
EBITDA	-34	-40	-44	-38	-29	-25
EBITDA Margin	-44.15%	-57.97%	-75.86%	-92.68%	-100%	-138.88%
D&A For EBITDA	1	1	0	1	0	0
EBIT	-35	-41	-44	-39	-29	-25
EBIT Margin	-45.45%	-59.42%	-75.86%	-95.12%	-100%	-138.88%
Effective Tax Rate	0%	0%	--	--	--	--

Follow-Up Questions

What are TELA Bio Inc's key financial statements?



What are the key financial ratios for TELA?



How is TELA Bio Inc's revenue broken down by segment or geography?



Is TELA Bio Inc profitable?



Does TELA Bio Inc have any liabilities?



How many outstanding shares for TELA Bio Inc?



Key Stats

Prev.Close

$0.8235

Open

$0.8423

Day's Range

$0.7625 - $0.8423

52 week range

$0.676 - $2.96

Volume

73.9K

Avg.Volume

257.8K

EPS (TTM)

-0.89

Dividend yield

Market Cap

$35.5M

What is TELA?

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.



Features

AI Copilot for Stock & Crypto

Resources